Circumvention of breast cancer resistance protein (BCRP)-mediated resistance to camptothecins in vitro using non-substrate drugs or the BCRP inhibitor GF120918

Autor: M, Maliepaard, M A, van Gastelen, A, Tohgo, F H, Hausheer, R C, van Waardenburg, L A, de Jong, D, Pluim, J H, Beijnen, J H, Schellens

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research. 7(4)

This study was aimed at characterizing the role of BCRP/MXR/ABCP (BCRP) in resistance of the human ovarian tumor cell lines T8 and MX3 to camptothecins more extensively and investigating whether resistance can be reversed by inhibiting BCRP by GF1209

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::69a01d6f5c500325798340dae24df5c4
https://pubmed.ncbi.nlm.nih.gov/11309344

Effects of c-myc oncogene modulation on differentiation of human small cell lung carcinoma cell lines

Autor: R C, van Waardenburg, C, Meijer, S J, Pinto-Sietsma, E G, de Vries, W, Timens, N M, Mulder

Publikováno v: Anticancer research. 18(1A)

Amplification and over-expression of oncogenes of the myc family are related to the prognosis of certain solid tumors such as small cell lung cancer (SCLC). For SCLC, c-myc is the oncogene most consistently found to correlate with the end stage behav

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::c8cab45cfd339f0aae0132553f5f57fe
https://pubmed.ncbi.nlm.nih.gov/9568061

Effects of c-myc oncogene modulation on drug resistance in human small cell lung carcinoma cell lines

Autor: R C, Van Waardenburg, J, Prins, C, Meijer, D R, Uges, E G, De Vries, N H, Mulder

Publikováno v: Anticancer research. 16(4A)

Small cell lung carcinoma (SCLC) is characterized by rapid development of resistance to drugs, such as cisdiamminedichloroplatinum (II) (cDDP) and anthracyclines. The molecular basis for resistance to cDDP and adriamycin (Adr) is poorly understood. O

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::82eab6cb58126b58732caab7e0d8a080
https://pubmed.ncbi.nlm.nih.gov/8712728

pH-Responsive, Self-Assembled Ruthenium Nanodrug: Dual Impact on Lysosomes and DNA for Synergistic Chemotherapy and Immunogenic Cell Death.

Autor: Lu Y; Department of Medicinal Chemistry, College of Pharmaceutical Sciences of Capital Medical University, Beijing, 100069, P. R. China.; Beijing Area Major Laboratory of Peptide and Small Molecular Drugs, Engineering Research Center of Endogenous Prophylactic of Ministry of Education of China, Beijing Laboratory of Biomedical Materials, Laboratory for Clinical Medicine, Capital Medical University, Beijing, 100069, P. R. China., Zhu D; Department of Medicinal Chemistry, College of Pharmaceutical Sciences of Capital Medical University, Beijing, 100069, P. R. China.; Beijing Area Major Laboratory of Peptide and Small Molecular Drugs, Engineering Research Center of Endogenous Prophylactic of Ministry of Education of China, Beijing Laboratory of Biomedical Materials, Laboratory for Clinical Medicine, Capital Medical University, Beijing, 100069, P. R. China., Hu B; Department of Medicinal Chemistry, College of Pharmaceutical Sciences of Capital Medical University, Beijing, 100069, P. R. China.; Beijing Area Major Laboratory of Peptide and Small Molecular Drugs, Engineering Research Center of Endogenous Prophylactic of Ministry of Education of China, Beijing Laboratory of Biomedical Materials, Laboratory for Clinical Medicine, Capital Medical University, Beijing, 100069, P. R. China., Chen R; Department of Medicinal Chemistry, College of Pharmaceutical Sciences of Capital Medical University, Beijing, 100069, P. R. China.; Beijing Area Major Laboratory of Peptide and Small Molecular Drugs, Engineering Research Center of Endogenous Prophylactic of Ministry of Education of China, Beijing Laboratory of Biomedical Materials, Laboratory for Clinical Medicine, Capital Medical University, Beijing, 100069, P. R. China., Wang X; Department of Medicinal Chemistry, College of Pharmaceutical Sciences of Capital Medical University, Beijing, 100069, P. R. China.; Beijing Area Major Laboratory of Peptide and Small Molecular Drugs, Engineering Research Center of Endogenous Prophylactic of Ministry of Education of China, Beijing Laboratory of Biomedical Materials, Laboratory for Clinical Medicine, Capital Medical University, Beijing, 100069, P. R. China., Xu X; Department of Core Facility Center, Capital Medical University, Beijing, 100069, P. R. China., Wang W; Beijing Institute of Hepatology, Beijing Youan Hospital, Capital Medical University, Beijing, 100069, P. R. China., Wu H; Xuanwu Hospital, Capital Medical University, Beijing, 100053, P. R. China., Wang Y; Department of Medicinal Chemistry, College of Pharmaceutical Sciences of Capital Medical University, Beijing, 100069, P. R. China.; Beijing Area Major Laboratory of Peptide and Small Molecular Drugs, Engineering Research Center of Endogenous Prophylactic of Ministry of Education of China, Beijing Laboratory of Biomedical Materials, Laboratory for Clinical Medicine, Capital Medical University, Beijing, 100069, P. R. China.

Publikováno v: Small (Weinheim an der Bergstrasse, Germany) [Small] 2024 Jun; Vol. 20 (24), pp. e2310636. Date of Electronic Publication: 2024 Feb 27.

Antimetastatic activity of novel ruthenium ( III) pyridine complexes.

Autor: Gu, Liwei¹, Li, Xiaodong¹, Ran, Qingsen¹, Kang, Chen¹, Lee, Canghai¹ leechhn@163.com, Shen, Jianying¹ jyshen@icmm.ac.cn

Publikováno v: Cancer Medicine. Oct2016, Vol. 5 Issue 10, p2850-2860. 11p.